Cantor Fitzgerald Upgrades HCA Healthcare, Inc.’s (HCA) Price Target, Citing Strategic Strengths

Cantor Fitzgerald elevated HCA Healthcare, Inc.’s (NYSE:HCA) price target to $444 from $405 on May 21, 2025, reaffirming an Overweight rating. The adjustment arises from to analyst’s confidence in the healthcare giant’s operational resilience and growth trajectory and reflects a 16% potential upside from the stock’s current closing price of $381.81.

Cantor Fitzgerald upgrades HCA Healthcare, Inc.’s price target to $444, Citing Strategic Strengths

A team of healthcare professionals in lab coats and masks meeting at a hospital ward.

HCA Healthcare, Inc. (NYSE:HCA), headquartered in Tennessee, is a leading American for-profit company, providing healthcare services through its 186 hospitals and approximately 2,400 care sites in 20 states and the United Kingdom.

The company holds a dominant position in the market, supported by its $92.72 billion market capitalization. According to Cantor Fitzgerald’s lead analysts, Sarah James, HCA Healthcare, Inc. (NYSE:HCA) demonstrated resilient performance across its service lines and significantly recovered from a $250 million EBITDA downturn in late 2024, attributed to hurricane-related disruptions.

With 85% of the patient volumes derived from these locations, the company aims to elevate the care sites per hospital from 13 to 20. HCA Healthcare, Inc. (NYSE:HCA) also has plans to cover the rural emergency services by making additional investments in transportation acquisitions like ambulance and helicopter fleets, and similar healthcare accessibilities.

Notably, the stock experienced a dip in pre-market trading despite better-than-expected Q1 2025 results, including a 20% year-over-year growth in EPS. However, pointing to strategic site expansions and geographic reach initiatives, Cantor Fitzgerald anticipates a long-term value from HCA Healthcare, Inc. (NYSE:HCA).

READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds

Disclosure: None.